Citigroup Downgrades Acadia Pharmaceuticals to Sell from Hold

Citigroup Downgraded ACADIA Pharmaceuticals Inc.(Nasdaq GM: ACAD). Citigroup has lowered its target on shares to $1.50 from $4.50 and confirms it to Sell after the company reported negative Phase 3 trial results for Pimavanserin in Parkinson's Disease Psychosis